Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol

Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol

Abstract Background Surgery is the only treatment option for operable gastric cancer. The CLASSIC and ACTS-GC studies showed that the 5-year overall survival (OS) of patients with stage III gastric cancer undergoing D2 gastrectomy is still very low. Whether adjuvant nanoparticle albumin-bound paclit...

Full description

Bibliographic Details
Main Authors: Xiangdong Cheng, Dan Wu, Nong Xu, Luchuan Chen, Zhilong Yan, Ping Chen, Lei Zhou, Jianfa Yu, Jiuwei Cui, Wei Li, Chang Wang, Wenming Feng, Yunhai Wei, Pengfei Yu, Yian Du, Jieer Ying, Zhiyuan Xu, Litao Yang, Yunli Zhang
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Gastric cancer
Adjuvant chemotherapy
Albumin-bound paclitaxel
S-1
Surgery
Survival
Online Access:https://doi.org/10.1186/s12885-020-07772-7

Internet

https://doi.org/10.1186/s12885-020-07772-7

Similar Items